SCHEMBL8199954

SCHEMBL8199954

CC(C)(C)OC(=O)N1CCc2cc(OCc3ccccc3)c(OCc3ccccc3)cc2C1Cc1ccc(-c2cccc(N)c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 5/20 0.48
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
MTNR1B P49286 3/20 0.42
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
DPP4 P27487 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
MTNR1A P48039 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5899110 0.91 CYP3A4 (0.51) GHSRCYP3A4CYP2D6CYP2C19MTNR1B
SCHEMBL8200141 0.86 CYP3A4 (0.51) GHSRCYP3A4CYP2D6CYP2C19MTNR1B
SCHEMBL8236839 0.85 GHSR (0.44) GHSRCYP3A4CYP2D6CYP2C19MTNR1B
SCHEMBL5899098 0.84 GHSR (0.47) GHSRCYP3A4CYP2D6CYP2C19MTNR1B
SCHEMBL5090978 0.84 CYP3A4 (0.64) CYP3A4CYP2D6CYP2C19MTNR1BMTNR1A
SCHEMBL3541010 0.84 CYP3A4 (0.64) CYP3A4CYP2D6CYP2C19MTNR1BMTNR1A
SCHEMBL8243627 0.83 GHSR (0.49) GHSRCYP3A4CYP2D6CYP2C19MTNR1B
SCHEMBL5899111 0.83 CYP3A4 (0.48) GHSRCYP3A4CYP2D6CYP2C19MTNR1B
SCHEMBL17821736 0.79 MTNR1B (0.55) CYP3A4CYP2D6CYP2C19MTNR1BLMNA
SCHEMBL5899118 0.79 CYP3A4 (0.47) GHSRCYP3A4CYP2D6CYP2C19MTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6043253-A TREATMENT OF DIABETES, OBESITY, LOWERING TRIGLYCERIDE OR CHOLESTEROL LEVELS, INCREASING HIGH DENSITY LIPOPROTEIN LEVELS OR DECREASING GUT MOTILITY, REDUCING NEUROGENIC INFLAMMATION, DEPRESSION OR GASTROINTESTINAL DISORDERS MERCK & CO., INC. (US) 2000-03-28 US disclosed